

Informazione Regolamentata n. 0696-18-2015	Data/Ora Ricezione 26 Febbraio 2015 07:26:01	MTA
--	--	-----

Societa' : CTI BIOPHARMA
Identificativo : 53514
Informazione
Regolamentata
Nome utilizzatore : CELLN01 - Villa
Tipologia : IRAG 09
Data/Ora Ricezione : 26 Febbraio 2015 07:26:01
Data/Ora Inizio : 26 Febbraio 2015 07:41:01
Diffusione presunta
Oggetto : CTI BioPharma to Report Fourth Quarter
and Full Year 2014

Testo del comunicato

Vedi allegato.



CTI BioPharma to Report Fourth Quarter and Full Year 2014 Financial Results on March 12, 2015

SEATTLE, Wash., February 26 , 2015—CTI BioPharma Corp. (NASDAQ and MTA: CTIC) announced today that it plans to report its fourth quarter and full year 2014 financial results on Thursday, March 12, 2015, after the close of the U.S. financial markets. Following the announcement, members of the management team will host a webcast conference call to discuss the results and provide a general corporate update at 4:30 p.m. EDT (1:30 p.m. PDT). Access to the event can be obtained as follows:

Thursday, March 12
1:30 p.m. PDT/4:30 p.m. EDT/9:30 p.m. CET
1-888-572-7025 (domestic)
+1 719-325-2463 (international)

To access the live audio webcast or the subsequent archived recording, visit CTI BioPharma's website, www.ctibiopharma.com. Webcast and telephone replays of the conference call will be available at approximately two hours after completion of the call. Callers can access the replay by dialing 1-888-203-1112 (domestic) or +1 719-457-0820 (international). The access code for the replay is 3193570. The telephone replay will be available until Thursday, March 19, 2015.

About CTI BioPharma

CTI BioPharma Corp. (NASDAQ and MTA: CTIC) is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers. CTI BioPharma has a commercial presence in Europe and a late-stage development pipeline, including pacritinib, CTI BioPharma's lead product candidate that is currently being studied in a Phase 3 program for the treatment of patients with myelofibrosis. CTI BioPharma is headquartered in Seattle, Washington, with offices in London and Milan under the name CTI Life Sciences Limited. For additional information and to sign up for email alerts and get RSS feeds, please visit www.ctibiopharma.com.

Source: CTI BioPharma Corp.

###

Contacts:

Monique Greer
+1 206-272-4343
mgreer@ctibiopharma.com

Ed Bell
+1 206-282-7100
ebell@ctibiopharma.com

In Europe:
CTI Life Sciences Limited, Milan Branch

Laura Villa
+39 02 94751572
lvilla@cti-lifesciences.com

Fine Comunicato n.0696-18

Numero di Pagine: 3